Male Mice Suffer Far Worse Zika Disease
Researchers at McMaster University infected male and female mice with the same Zika virus at the same dose and found the males developed far worse neurological disease, McMaster announced on Monday, November 16, 2026. The finding comes from a mouse study published in the Journal of Infectious Diseases. It is not a human trial.
Edited and fact-checked by Stephen Sprague
The virus load was the same in both sexes. The damage was not. McMaster's mouse study puts the difference in the immune response itself, and the human evidence is still to come.
Male mice developed far worse Zika disease than female mice given the same virus at the same dose, McMaster University researchers report.
The study was published in the Journal of Infectious Diseases and announced by McMaster on Monday, November 16, 2026. The team works at the Michael G. DeGroote Institute for Infectious Disease Research. Professor Ali Ashkar is the principal investigator, and PhD student Alexa Mansour is the paper's first author. The evidence is from mice. No patients were enrolled, and nothing in the study tests a treatment.
The design removes the usual excuses. The male and female mice were nearly genetically identical, the exact same age, and infected with the same virus taken from the same vial at equal amounts, Ashkar says. The males were significantly more susceptible to severe neurological complications, including weakness and paralysis. The females largely were not.
The viral load does not explain the gap. Testing showed the male and female mice carried comparable levels of Zika in both their blood and their brains. The difference sits in the response, not the infection. Ashkar's read is that the male immune system responds more strongly to these infections, and the inflammation at the site of infection does more damage as a consequence.
The finding was an accident, and the accident is the method's best credential. The lab had studied Zika in mice over an extended period when the virus's trademark neurological symptoms stopped appearing. The cohort in use at that point was all female. When the researchers reintroduced male mice, the severe neurological complications returned. A result the team tried to explain away survived its own controls.
The limits are plain. This is one virus, in one mouse model, at one institution. It does not show that men with Zika fare worse than women with Zika, and it does not measure outcomes for COVID-19, influenza, or West Nile virus in people. McMaster frames the paper as adding to a body of studies reporting worse male outcomes in those infections. That framing is the university's, and the human data behind it sits outside this study.
Mansour's conclusion is about study design before it is about any one virus. She says the findings, read with the related literature, mean it's really important to consider biological sex in the context of infectious disease going forward. A trial or an animal study that records sex and never analyzes it holds data it refuses to read. This paper exists because one lab noticed its symptom data had quietly split along that line.
Ashkar argues the clinical step does not need new drugs. He says physicians should control inflammation early in male patients with acute viral infections, using anti-inflammatory medications that are already approved and effective. That is a proposal from the investigator, not a guideline, and no trial in this paper tests it.
What the study settles is narrower and still useful. In a controlled infection where dose, age, and genetics were held constant, biological sex changed the severity of the disease. Any Zika study that pools male and female animals without separating them is now averaging away the effect it claims to measure.
Sources
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.